BusinessBiothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in TumorsBy Nasdaq OMXApr 16, 2018, 1:01 PM UTC